Selumetinib: Clinical Trials

87 trials of Selumetinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

47 completed, 13 active not recruiting, 12 terminated, 5 recruiting. 54 Phase 2, 40 Phase 1, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 254Completed 27, Terminated 8, Active not recruiting 6, Not yet recruiting 4, Recruiting 4, Withdrawn 3, Unknown 2
Phase 140Completed 23, Active not recruiting 6, Terminated 5, Recruiting 4, Unknown 2
Phase 33Active not recruiting 2, Terminated 1

Follow Selumetinib: new trials by email Literature Review of Selumetinib trials Research Report on Selumetinib

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma
Biospecimen Collection, Diagnostic Imaging Testing, Echocardiography Test - Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)312027-06-012026-10-22
Selumetinib for NF2-Related Schwannomatosis
Selumetinib - Neurofibromatosis Type 2, NF2
Phase 2Not yet recruitingBeijing Tiantan Hospital202026-12-012026-10-28
Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST
APG-115, Selumetinib - Malignant Peripheral Nerve Sheath Tumor (MPNST), Neurofibromatosis 1 (NF1)
Phase 1 / Phase 2RecruitingAeRang Kim452026-06-012026-07-27
Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1
Selumetinib - Neurofibromatosis 1, Plexiform Neurofibroma
Phase 2RecruitingUniversity of Alabama at Birmingham2002025-08-272026-05-29
Low-dose Selumetinib for the Treatment of Plexiform Neurofibromas in Chinese Children
Selumetinib - Plexiform Neurofibromas (PN)
Phase 2Not yet recruitingWest China Hospital502025-01-012025-01-08
The Clinical Study of the Treatment of Patients With Type I Neurofibromatosis With Smetinib Hydrosulfate Capsule
Selumetinib - Neurofibromatosis 1
Phase 2Not yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University192024-09-302024-10-01
Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule
Selumetinib - Neurofibromatosis 1
Phase 2Not yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University332024-09-302024-10-01
Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled Study
Selumetinib, Placebo - Neurofibromatosis Type 1, Plexiform Neurofibromas
Phase 2WithdrawnAstraZeneca2023-08-312023-08-14
Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
Selumetinib, Placebo - Neurofibromatosis 1, Plexiform Neurofibroma (PN)
Phase 3Active not recruitingAstraZeneca1452021-11-192026-11-12
Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas
Selumetinib - Neurofibromatosis Type 1
Phase 1Active not recruitingAstraZeneca242021-07-212026-08-20
A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
Selumetinib - Neurofibromatosis 1, Neurofibroma Plexiform
Phase 1Active not recruitingAstraZeneca322020-12-162026-08-18
Selumetinib Paediatric NF1 Japan Study
Selumetinib - Neurofibromatosis Type 1
Phase 1CompletedAstraZeneca122020-08-312023-04-26
SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
Selumetinib, Sirolimus - Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1
Phase 2CompletedSarcoma Alliance for Research through Collaboration212019-10-022026-05-27
Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours
Selumetinib - Neurofibromatosis Type 1, Plexiform Neurofibroma
Phase 1 / Phase 2CompletedGreat Ormond Street Hospital for Children NHS Foundation Trust142019-09-262024-04-04
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
Osimertinib, Savolitinib, Gefitinib - Non-Small Cell Lung Cancer
Phase 2Active not recruitingAstraZeneca2472019-06-252025-01-30
Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer
Durvalumab, Selumetinib, Tremelimumab - Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Phase 1 / Phase 2CompletedM.D. Anderson Cancer Center402019-04-012026-10-23
Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)
Selumetinib, Pembrolizumab - Advanced/Metastatic Solid Tumors
Phase 1TerminatedMerck Sharp & Dohme LLC322019-03-182024-11-07
Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)
MK-8353, Selumetinib - Solid Tumors
Phase 1CompletedMerck Sharp & Dohme LLC302019-02-222023-07-27
AMTEC IIT: Phase 2 Multiarm Study in TNBC
Biopsy, Capivasertib, Ceralasertib - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Phase 2TerminatedGordon Mills, MD, PhD242018-12-122026-02-25
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
Azacitidine, Selumetinib - Chronic Myeloid Leukemia, Myelofibroses
Phase 1RecruitingUniversity of Chicago182018-09-042025-12-29

Showing 20 of 87. Sign in to see all of them.

Conditions studied

Carcinoma, Non-Small-Cell Lung (15)  ·  Neurofibromatosis 1 (14)  ·  Neurofibroma, Plexiform (8)  ·  Melanoma (6)  ·  Breast Neoplasms (5)  ·  Colorectal Neoplasms (4)  ·  Lung Neoplasms (4)  ·  Pancreatic Neoplasms (4)  ·  Biliary Tract Neoplasms (3)  ·  Carcinoma, Hepatocellular (3)  ·  Gallbladder Neoplasms (3)  ·  Neoplasm Metastasis (3)  ·  Neoplasms (3)  ·  Bile Duct Neoplasms (2)  ·  Ependymoma (2)

Sponsors

National Cancer Institute (NCI) (27)  ·  AstraZeneca (24)  ·  M.D. Anderson Cancer Center (4)  ·  Merck Sharp & Dohme LLC (3)  ·  Canadian Cancer Trials Group (2)  ·  Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (2)  ·  UNICANCER (2)  ·  University of Birmingham (2)  ·  Academic and Community Cancer Research United (1)  ·  AeRang Kim (1)  ·  Beijing Tiantan Hospital (1)  ·  Children's Hospital Medical Center, Cincinnati (1)  ·  Dana-Farber Cancer Institute (1)  ·  Gordon Mills, MD, PhD (1)  ·  Great Ormond Street Hospital for Children NHS Foundation Trust (1)

Countries

United States (55)  ·  United Kingdom (17)  ·  Canada (12)  ·  France (9)  ·  Spain (8)  ·  Italy (6)  ·  Netherlands (6)  ·  Brazil (5)  ·  China (4)  ·  Denmark (4)  ·  Germany (4)  ·  Japan (4)  ·  Poland (4)  ·  Sweden (4)  ·  Belgium (3)

Top investigators

AeRang Kim, MD, PhD (2)  ·  Gabriella Mariani, MD (2)  ·  Paul Chapman (2)  ·  Tanios Bekaii-Saab (2)  ·  Zhiquan Huang, doctoral (2)  ·  Alan Ho, M.D., PHD (1)  ·  Alan L Ho (1)  ·  Alice P. Chen, MD (1)  ·  Andrew Ko (1)  ·  Arun Rajan, M.D. (1)  ·  Barbara Lynn Melosky (1)  ·  Bert O'Neil (1)  ·  Birgit Geoerger, MD (1)

Results publications

PMID 15683544, PMID 17105749, PMID 21996156, PMID 22353803, PMID 26851632, PMID 28029918, PMID 28230061, PMID 28409229, PMID 31010905, PMID 31582003, PMID 32187457, PMID 32379297, PMID 33354735, PMID 33863389, PMID 34541874, PMID 21519026, PMID 23077008, PMID 23200175, PMID 23261356, PMID 23735514, PMID 24178622, PMID 24938562, PMID 25516890, PMID 25667274, PMID 25887099, PMID 25892646, PMID 26028668, PMID 26125448, PMID 26410619, PMID 26837474, PMID 26912134, PMID 27751676, PMID 27921276, PMID 27978579, PMID 28492898, PMID 29718344, PMID 30317534, PMID 31151904, PMID 31200828, PMID 31538815, PMID 32027845, PMID 32067679, PMID 32203306, PMID 32669708, PMID 33536190, PMID 33748440, PMID 33892407, PMID 34347542, PMID 34389237, PMID 34543871

NIH funding

N01CM62208 (5), N01CM00070 (3), N01CM00071 (3), N01CM00100 (3), N01CM62201 (3), N01CM62206 (3), P30CA076292 (3), 2014 (2), 2016 (2), N01CM62207 (2), P30CA008748 (2), P30CA015083 (2), U10CA027469 (2), U10CA180868 (2), UM1CA186686 (2)